However, the first clinical trial that attempted to inhibit HSP90 was a disappointment: patients developed serious adverse effects, and the relevance of HSP90 inhibition as a therapeutic strategy in MPN was called into question [52]. The gene discussed is HSP90AA1; the disease is myeloproliferative disorder.